Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
2.560
-0.070 (-2.66%)
At close: Nov 26, 2025, 4:00 PM EST
2.590
+0.030 (1.17%)
After-hours: Nov 26, 2025, 5:41 PM EST
Traws Pharma Revenue
Traws Pharma had revenue of $2.85M in the twelve months ending September 30, 2025, up 1,159.29% year-over-year. In the year 2024, Traws Pharma had annual revenue of $226.00K.
Revenue (ttm)
$2.85M
Revenue Growth
+1,159.29%
P/S Ratio
5.99
Revenue / Employee
$406,571
Employees
7
Market Cap
20.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 226.00K | - | - |
| Dec 31, 2023 | 226.00K | - | - |
| Dec 31, 2022 | 226.00K | - | - |
| Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
| Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TRAW News
- 27 days ago - ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials - PRNewsWire
- 5 weeks ago - Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. - PRNewsWire
- 6 weeks ago - Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - GlobeNewsWire
- 3 months ago - Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - GlobeNewsWire
- 3 months ago - Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - GlobeNewsWire
- 3 months ago - Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewsWire
- 5 months ago - Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions - GlobeNewsWire